The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis
Experimental & Molecular Medicine
;
: e40-2013.
Article
Dans Anglais
| WPRIM
| ID: wpr-71809
ABSTRACT
In this study, we examined the therapeutic effects of an immune-stimulating peptide, WKYMVm, in ulcerative colitis. The administration of WKYMVm to dextran sodium sulfate (DSS)-treated mice reversed decreases in body weight, bleeding score and stool score in addition to reversing DSS-induced mucosa destruction and shortened colon. The WKYMVm-induced therapeutic effect against ulcerative colitis was strongly inhibited by a formyl peptide receptor (FPR) 2 antagonist, WRWWWW, indicating the crucial role of FPR2 in this effect. Mechanistically, WKYMVm effectively decreases intestinal permeability by stimulating colon epithelial cell proliferation. WKYMVm also strongly decreases interleukin-23 and transforming growth factor-beta production in the colon of DSS-treated mice. We suggest that the potent immune-modulating peptide WKYMVm and its receptor FPR2 may be useful in the development of efficient therapeutic agents against chronic intestinal inflammatory diseases.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Oligopeptides
/
Perméabilité
/
Rectocolite hémorragique
/
Adjuvants immunologiques
/
Facteur de croissance transformant bêta
/
Côlon
/
Cellules Caco-2
/
Récepteurs aux peptides formylés
/
Prolifération cellulaire
/
Interleukine-23
Limites du sujet:
Animaux
/
Humains
langue:
Anglais
Texte intégral:
Experimental & Molecular Medicine
Année:
2013
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS